Reference : (18)F- FDG PET/CT joint assessment of early therapeutic response in rheumatoid arthri...
Scientific journals : Article
Human health sciences : Rheumatology
Human health sciences : Radiology, nuclear medicine & imaging
http://hdl.handle.net/2268/225040
(18)F- FDG PET/CT joint assessment of early therapeutic response in rheumatoid arthritis patients treated with rituximab.
English
Fosse, Pacome [Centre Hospitalier Universitaire d'Angers - CHU ANGERS > > Service de Médecine nucléaire > >]
KAISER, Marie-Joëlle mailto [Centre Hospitalier Universitaire de Liège - CHU > > Service de rhumatologie >]
Namur, Gauthier [Clinique Saint-Joseph (Liège) > > Service de Médecine nucléaire > >]
DE SENY, Dominique mailto [Centre Hospitalier Universitaire de Liège - CHU > > Service de rhumatologie >]
Malaise, Michel mailto [Université de Liège - ULiège > Département des sciences cliniques > Rhumatologie >]
Hustinx, Roland mailto [Université de Liège - ULiège > Département des sciences cliniques > Médecine nucléaire >]
2018
European journal of hybrid imaging
2
1
6
Yes
International
2510-3636
2510-3636
England
[en] 18F- FDG ; PET/CT ; Rheumatoid arthritis ; Rituximab
[en] Background: (18)F-FDG PET/CT has been proposed in the evaluation of the disease activity in rheumatoid arthritis (RA). The goals of this study were to evaluate the reproducibility of the technique, to compare metabolic parameters to clinical, biological and ultrasonographic parameters before and after treatment and to evaluate whether the early metabolic response was related to the outcome. (18)F- FDG PET/CT of the hands, wrists and knees was obtained in 15 patients with anti-TNFalpha refractory RA, at baseline and 16 weeks after treatment with rituximab. The number of PET-positive joints (PET+ joints), the cumulative standard uptake value (cSUV) and the composite index (CI) were defined. The composite clinical index DAS28, CRP serum levels and the number of joints positive at ultrasonography (US+ joints) and the cumulative synovial thickness (CST) were also assessed at baseline and week 24. Results: High interobserver agreement was observed, both at baseline and after treatment. The number of PET+ joints was not correlated with the number of joints tender or swollen. The 3 metabolic parameters were strongly correlated with US, CRP and DAS28 at baseline and with US and CRP (CSUV, CI) at week 16, but no longer with the DAS28 index. The metabolic response based on the change in the visual PET/CT joint analysis predicted the outcome with a high negative predictive value of 91%, with a 91% specificity, and an 86% accuracy. Conclusions: These preliminary data suggest that (18)F- FDG PET/CT is a reproducible and accurate tool for evaluating disease activity in refractory rheumatoid arthritis and its non-response to rituximab. The correlation obtained with US joint assessment gives relevance to objective diseased joints through imaging techniques.
Researchers ; Professionals ; Students
http://hdl.handle.net/2268/225040
10.1186/s41824-017-0022-y

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
18F- FDG PET-CT joint assessment of early therapeutic response in rheumatoid arthritis patients treated with rituximab.pdfPublisher postprint619.8 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.